Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Language
Year
  • 1
    Language: English
    In: Physical review letters, 23 August 2013, Vol.111(8), pp.084802
    Description: Electron and stochastic cooling are proven methods for cooling low-energy hadron beams, but at present there is no way of cooling hadrons as they near the TeV scale. In the 1980s, Derbenev suggested that electron instabilities, such as free-electron lasers, could create collective space charge fields strong enough to correct the hadron energies. This Letter presents a variation on Derbenev's electron cooling scheme using the microbunching instability as the amplifier. The large bandwidth of the instability allows for faster cooling of high-density beams. A simple analytical model illustrates the cooling mechanism, and simulations show cooling rates for realistic parameters of the Large Hadron Collider.
    ISSN: 00319007
    E-ISSN: 1079-7114
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Nature Biotechnology, 2011, Vol.29(4), p.293
    Description: On March 7, the board of directors of Genzyme recommended that shareholders accept a buyout offer from global pharma giant Sanofi-aventis of Paris, presumably ending the most visible and noisy acquisition negotiation in biotech history. When finalized, it will become the second largest biotech transaction...
    Keywords: Biotechnology–Economics ; Biotechnology–Organization & Administration ; Drug Industry–Economics ; Drug Industry–Organization & Administration ; Health Care Sector–Economics ; Humans–Economics ; Biotechnology ; Acquisitions & Mergers ; Genzyme Corp ; Sanofi-Aventis SA;
    ISSN: 1087-0156
    E-ISSN: 15461696
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Article
    Article
    In: Nature Biotechnology, 2011, Vol.29(2), p.97
    Description: Three people affected by shortages in Genzyme's drug for Fabry disease failed to convince the NIH to use 'march-in rights' to break manufacturing patents held by the biotech company and grant a new license to third parties to deal with the problem. The enzyme replacement therapy Fabrazyme is the only...
    Keywords: Pharmaceutical Industry ; Biotechnology Industry ; Prescription Drug Plans ; Enzymes ; Genzyme Corp;
    ISSN: 1087-0156
    E-ISSN: 15461696
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: Nature Biotechnology, 2011, Vol.29(8), p.676
    Description: For the second time in a year, a panel of US Food & Drug Administration (FDA) advisors has stated that Genentech's blockbuster cancer drug Avastin (bevacizumab) confers no meaningful clinical benefit when used with chemotherapy as an initial treatment for metastatic breast cancer and that its approval...
    Keywords: Angiogenesis Inhibitors–Adverse Effects ; Angiogenesis Inhibitors–Therapeutic Use ; Antibodies, Monoclonal, Humanized–Adverse Effects ; Antibodies, Monoclonal, Humanized–Therapeutic Use ; Breast Neoplasms–Blood Supply ; Breast Neoplasms–Drug Therapy ; Drug Approval–Economics ; Drug Industry–Legislation & Jurisprudence ; Drug Industry–Legislation & Jurisprudence ; Female–Legislation & Jurisprudence ; Humans–Legislation & Jurisprudence ; United States–Legislation & Jurisprudence ; United States Food & Drug Administration–Legislation & Jurisprudence ; Regulatory Agencies ; FDA Approval ; Breast Cancer ; Pharmaceutical Industry ; Prescription Drugs ; Metastasis ; Angiogenesis Inhibitors ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Food & Drug Administration–FDA;
    ISSN: 1087-0156
    E-ISSN: 15461696
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Article
    Article
    In: Nature Biotechnology, 2011, Vol.29(1), p.3
    Description: Pfizer is rolling out a grand plan to draw out drug-development-ready research from academia through a series of collaborations with leading medical centers worldwide. The first collaboration, announced in November, is with the University of California, San Francisco (UCSF), to which the pharma giant...
    Keywords: Biomedical Research–Methods ; Biotechnology–Organization & Administration ; Cooperative Behavior–Organization & Administration ; Drug Discovery–Organization & Administration ; Drug Industry–Organization & Administration ; Humans–Organization & Administration ; Organizational Affiliation–Organization & Administration ; Research Support As Topic–Organization & Administration ; United States–Organization & Administration ; Universities–Organization & Administration ; Educational Partnerships ; Research Centers ; Pharmaceutical Industry ; Biotechnology ; Researchers ; Pfizer Inc ; Glaxosmithkline Plc ; University of California-San Francisco;
    ISSN: 1087-0156
    E-ISSN: 15461696
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Nature Medicine, 2011, Vol.17(3), p.233
    Description: The US Food and Drug Administration sent shockwaves through the medical community last year when it stated its plans to revoke marketing approval for the monoclonal antibody treatment Avastin (bevacizumab) in combination with the chemotherapy drug paclitaxel for first-line treatment of metastatic breast...
    Keywords: Angiogenesis Inhibitors–Therapeutic Use ; Antibodies, Monoclonal–Therapeutic Use ; Antibodies, Monoclonal, Humanized–Legislation & Jurisprudence ; Biotechnology–Drug Therapy ; Drug Approval–Drug Therapy ; Drug Industry–Drug Therapy ; Humans–Drug Therapy ; Neoplasms–Drug Therapy ; United States–Drug Therapy ; United States Food & Drug Administration–Drug Therapy ; FDA Approval ; Pharmaceutical Industry ; Prescription Drugs ; Hearings & Confirmations ; Angiogenesis Inhibitors ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Food & Drug Administration–FDA ; Genentech Inc;
    ISSN: 1078-8956
    E-ISSN: 1546170X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: Language, Speech, & Hearing Services in Schools, Jan, 2011, Vol.42, p.77(4)
    Description: Purpose: This article proposes some recommendations to enable clinicians to balance certainty and uncertainty when evaluating the currency and effectiveness of their treatment approaches. Method: I offer the following advice: (a) Question the authority of the information previously learned in one's career; (b) be cognizant of what we do not yet know about best clinical practice; (c) understand that knowledge of "best practices" is both temporary and relative; (d) enable access to new information by the use of electronic alerts; (e) be flexible in reading new clinical reports, keeping an open mind as to their value; (f) get the clinically relevant details of new approaches by reading the full reports; and (g) employ, and then evaluate the outcomes of, new approaches used in treating individuals on our caseload. Results: Examples are provided to show that proactive participation in research-alert programs can enable clinicians to access emerging, clinically relevant information, some of which is controversial. Staying abreast of such information is more efficient than performing guided searches for information as challenging cases arise. Conclusions: Applications of these recommendations should enable practicing clinicians to entertain new, clinically useful concepts while not taxing the limited time that clinicians typically have to engage in continuing education. KEY WORDS: evidence-based practice, information literacy, continuing education, clinical decision making
    Keywords: Evidence-based Medicine -- Forecasts And Trends ; Speech Therapists -- Beliefs, Opinions And Attitudes ; Speech Therapists -- Practice ; Speech Therapists -- Vocational Guidance ; Medical Practice -- Management ; Uncertainty -- Evaluation
    ISSN: 0161-1461
    Source: Cengage Learning, Inc.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Language: English
    In: Language, Speech, & Hearing Services in Schools, Jan, 2011, Vol.42, p.77(4)
    Description: Purpose: This article proposes some recommendations to enable clinicians to balance certainty and uncertainty when evaluating the currency and effectiveness of their treatment approaches. Method: I offer the following advice: (a) Question the authority of the information previously learned in one's career; (b) be cognizant of what we do not yet know about best clinical practice; (c) understand that knowledge of "best practices" is both temporary and relative; (d) enable access to new information by the use of electronic alerts; (e) be flexible in reading new clinical reports, keeping an open mind as to their value; (f) get the clinically relevant details of new approaches by reading the full reports; and (g) employ, and then evaluate the outcomes of, new approaches used in treating individuals on our caseload. Results: Examples are provided to show that proactive participation in research-alert programs can enable clinicians to access emerging, clinically relevant information, some of which is controversial. Staying abreast of such information is more efficient than performing guided searches for information as challenging cases arise. Conclusions: Applications of these recommendations should enable practicing clinicians to entertain new, clinically useful concepts while not taxing the limited time that clinicians typically have to engage in continuing education. KEY WORDS: evidence-based practice, information literacy, continuing education, clinical decision making
    Keywords: Evidence-based Medicine -- Forecasts And Trends ; Speech Therapists -- Beliefs, Opinions And Attitudes ; Speech Therapists -- Practice ; Speech Therapists -- Vocational Guidance ; Medical Practice -- Management ; Uncertainty -- Evaluation
    ISSN: 0161-1461
    Source: Cengage Learning, Inc.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: Nature Biotechnology, 2014, Vol.32(9), p.853
    Description: The July approval of the histone deacetylase (HDAC) inhibitor Beleodaq (belinostat) marks the third HDAC inhibitor to gain registration in the US and the first in almost five yearsall for treating rare T-cell lymphomas. For small biotech Spectrum Pharmaceuticals of Henderson, Nevada, gaining accelerated approval from the US Food and Drug Administration (FDA) for Beleodaq following a single-arm, open label, nonrandomized trial is a coup, even if estimates put the commercial potential for Beleodaq at around $30 million a year, at best.
    Keywords: Inhibitor Drugs ; Lymphomas ; Cells ; Clinical Trials ; Biotechnology Industry;
    ISSN: 1087-0156
    E-ISSN: 15461696
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    In: Nature Biotechnology, 2014, Vol.32(9), p.855
    Description: The US Food and Drug Administration (FDA) has told Congress that it intends to enforceits oversight over laboratory-developed tests (LDTs). On July 31, the agency announced that it will publish draft guidelines on how it will regulate LDTs. The FDA has sidestepped bringing laboratory tests under its...
    Keywords: Government Agencies ; Laboratory Animals ; Tests ; Food & Drug Administration–FDA;
    ISSN: 1087-0156
    E-ISSN: 15461696
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages